Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Metronidazole 400mg tablets
0501110C0AAAJAJ
|
Metronidazole (Systemic) | Metronidazole | Infections | 95,681 |
|
Metronidazole 0.75% gel
1310012K0AAARAR
|
Metronidazole (Topical) | Metronidazole | Skin | 29,000 |
|
Metronidazole 0.75% cream
1310012K0AAAXAX
|
Metronidazole (Topical) | Metronidazole | Skin | 20,600 |
|
Rozex 0.75% gel
1310012K0BDAAAR
|
Rozex | Metronidazole | Skin | 15,822 |
|
Metronidazole 0.75% vaginal gel
0702020X0AAAAAA
|
Metronidazole (Vaginal) | Metronidazole | Obstetrics, Gynaecology and Urinary-Tract Disorders | 13,242 |
|
Rozex 0.75% cream
1310012K0BDABAX
|
Rozex | Metronidazole | Skin | 7,402 |
|
Metrogel 0.75% gel
1310012K0BCAAAR
|
Metrogel | Metronidazole | Skin | 4,739 |
|
Metronidazole 200mg tablets
0501110C0AAAIAI
|
Metronidazole (Systemic) | Metronidazole | Infections | 3,860 |
|
Metronidazole 200mg/5ml oral suspension
0501110C0AAAEAE
|
Metronidazole (Systemic) | Metronidazole | Infections | 3,439 |
|
Metronidazole 500mg tablets
0501110C0AABHBH
|
Metronidazole (Systemic) | Metronidazole | Infections | 2,757 |
|
Anabact 0.75% gel
1310012K0BEAAAR
|
Anabact | Metronidazole | Skin | 1,189 |
|
Zidoval 0.75% vaginal gel
0702020X0BBAAAA
|
Zidoval | Metronidazole | Obstetrics, Gynaecology and Urinary-Tract Disorders | 312 |
|
Metrosa 0.75% gel
1310012K0BKAAAR
|
Metrosa | Metronidazole | Skin | 296 |
|
Acea 0.75% gel
1310012K0BJAAAR
|
Acea | Metronidazole | Skin | 137 |
|
Metronidazole 500mg suppositories
0501110C0AAAGAG
|
Metronidazole (Systemic) | Metronidazole | Infections | 122 |
|
Metronidazole 1g suppositories
0501110C0AAAHAH
|
Metronidazole (Systemic) | Metronidazole | Infections | 70 |
|
Flagyl 400mg tablets
0501110C0BCABAJ
|
Flagyl | Metronidazole | Infections | 23 |
|
Rosiced 0.75% cream
1310012K0BLAAAX
|
Rosiced | Metronidazole | Skin | 11 |
|
Metronidazole 100mg/5ml oral suspension
0501110C0AABTBT
|
Metronidazole (Systemic) | Metronidazole | Infections | 6 |
|
Flagyl 1g suppositories
0501110C0BCAEAH
|
Flagyl | Metronidazole | Infections | 3 |
|
Metronidazole 200mg/5ml oral solution
0501110C0AABQBQ
|
Metronidazole (Systemic) | Metronidazole | Infections | 3 |
|
Flagyl 200mg tablets
0501110C0BCAAAI
|
Flagyl | Metronidazole | Infections | 2 |
|
Flagyl 500mg suppositories
0501110C0BCADAG
|
Flagyl | Metronidazole | Infections | 2 |
|
Zyomet 0.75% gel
1310012K0BIAAAR
|
Zyomet | Metronidazole | Skin | 2 |
|
Metronidazole 1% cream
1310012K0AABJBJ
|
Metronidazole (Topical) | Metronidazole | Skin | 1 |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.